XBI, the SPDR S&P Biotech ETF, enters the final days of September with a striking disconnect: options traders are at their most bearish in twelve months, yet the lending market has quietly loosened over the past week.
The options picture is the sharpest signal right now. The put/call ratio hit 1.41 on Thursday — more than two standard deviations above its 20-day average of 1.24, making it the highest defensive reading of the past year outside of the 52-week peak at 1.44. That isn't noise. Investors have been steadily adding downside protection since mid-August, when the PCR was running near 1.11. The drift higher has been consistent and purposeful, not a single-day spike. For a broad biotech ETF, that kind of persistent put accumulation tends to reflect genuine sector-level unease rather than hedges on individual names.
The short interest picture tells a more complicated story. At 112.9% of float, short positioning in XBI is extreme by any measure — and it ticked up roughly 2% on the week to 75.7 million shares. But borrow conditions have actually loosened materially. Availability climbed from around 65% three weeks ago to 130% as of Wednesday, meaning there are now more shares available to borrow than the current short interest base. That loosening happened even as shorts pushed the week's position higher, which points to a genuine increase in shares coming into the lending pool rather than a reduction in bearish demand. Cost to borrow is a modest 2.07%, roughly flat on the week, reinforcing that there's no meaningful squeeze pressure building in the plumbing. The ORTEX short score of 76.7 — holding in elevated territory all month — captures the overall lean of this positioning without implying the situation has reached a critical threshold.
What's worth watching is the persistence of that PCR drift alongside a month that has seen XBI fall 8.3% to $155.03. The ETF is down about 1% on the week and gave back another 0.65% on Friday. Short sellers trimmed positions meaningfully through early September — shares short peaked near 78.7 million on August 21 and declined steadily through to mid-September — before beginning to rebuild this week. The rebuild is modest so far, but it coincides with the sharpest options defensiveness of the year. The next meaningful data point is whether availability stays loose or tightens back toward the early-September levels that briefly approached 15% — a much more constrained lending environment than today's.
See the live data behind this article on ORTEX.
Open XBI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
